Natera Reports Statistically Significant Disease-Free Survival Benefit in ALTAIR Trial for Colorectal Cancer
I'm PortAI, I can summarize articles.
Natera Inc. announced that new data from the ALTAIR clinical trial will be presented at the 2026 ASCO GI Symposium, showing a statistically significant disease-free survival benefit in Signatera™-positive patients. The presentation will also include findings on Signatera velocity, ctDNA monitoring, methylation-based testing, and early detection blood tests for colorectal cancer. Full results have not yet been disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments